About Peptide Debrief

Peptide Debrief explains peptide research and regulation in plain English. We cover the compounds people are searching for, such as retatrutide, tirzepatide and semaglutide, and the FDA and clinical trial news that affects them.

Every guide cites the original studies, trial registries or FDA documents, and clinical content is reviewed by a physician on our medical review team before it is published. Read our editorial policy for the full process.

Our team

Peptide Debrief Editorial Team

Editorial Team

Our editors research and write every article from primary sources: peer-reviewed studies, clinical trial registries and FDA documents. Clinical content is reviewed by a physician before publication. See our editorial policy for how we work.

Contact

Corrections, questions or press: editor@peptidedebrief.com.